Gis Data Articles & Analysis: Older

3 news found

GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.

Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced ...

Jun. 15, 2022

ByGI Dynamics, Inc.

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced The Extent And Severity Of Post-Surgical Intraabdominal Adhesions By 93%

(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) ...

Mar. 16, 2022

ByPalisade Bio

Results from Axial Therapeutics Phase1b/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint and Reduced Irritability and Other Symptoms

In addition, significant improvements in subjects with high irritability or high anxiety were observed, as well as improvements in social withdrawal and gastrointestinal symptoms (GI). Specifically, the data showed that AB-2004 reduced several key GI neuroactive microbial metabolites (NMMs™) measured in plasma and urine. ...

Dec. 3, 2020

ByAxial Therapeutics Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you